带HSV—tk基因的重组腺病毒基因治疗小鼠B16黑色素瘤的实验研究

我父成功开展了携带单纯疹疹Ⅰ型病毒胸腺嘧啶激酶基因（Ｈｅｒｐｅｓｓｉｍｐｌｅｘｖｉｒｕｓｔｈｙ－ｍｎｉｄｉｎｅｋｉｎａｓｅ，ＨＳＶ－ｔｋ）的复制缺陷型重组腺病毒Ａｄ（ＨＳＶ－ｔｋ）结合使用ＧＣＶ治疗Ｃ５７ＢＬ／６小鼠Ｂ１６黑色素瘤的离体及动物试验。

Gene therapy using recombinant adenovirus carrying herpes simplex-thymidine kinase gene to treat mouse B 16 melanoma in vivo]

Adenoviral transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene followed by administration of gancyclovir (GCV) was used to treat B 16 melanoma of C 57 BL/6 mice. B 16 murine melanoma cells transduced in vitro by a recombinant replication-defective adenovirus containing the HSV-tk gene Ad(HSV-tk)] were highly sensitive to cell killing by GCV, and the IC50 was 0.1 microgram/ml. A significant "bystander effect" was observed when Ad(HSV-tk)-infected and -uninfected B 16 cells were mixed. Direct tumoral injection of Ad (HSV-tk) into established B 16 melanoma in C 57 BL/6 mice and subsequent treatment for 6 d with GCV resulted in the growth regression and necrosis of tumor nodules, and the tumor size was approximately reduced to one-twenty fifth of that of control animals. Finally, the safety of this treatment approach was demonstrated by limited dissemination of virus using sensitive RT-PCR. HSV-tk mRNA was detected only in the tumor nodule. These data indicated that gene therapy using Ad(HSV-tk)/GCV may function as an effective and safe alternative for treatment of melanoma in vivo.